The global Hereditary Angioedema Therapeutic Market size is expected to reach USD 4.2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting an 8.1% CAGR during the forecast period. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market.
Patient
advocacy organizations affiliated to HAE International (HAEi) are focusing on
campaigns through both print and social media in order to raise awareness
levels for hereditary angioedema. HAEi has also introduced family testing tools
for improving patient awareness levels, which is likely to help in providing
accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology
companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in
development of therapies for HAE have also lent their support and collaborated
with the hereditary angioedema community so as to create effective diagnosis
process and treatment for the condition.
Universities
in different countries across the globe are collaborating with each other in
order to develop new therapies for the management of hereditary angioedema
attacks. For instance, in 2018, 26 universities from Europe, Australia, and
Canada collaborated on an international study to develop a novel oral therapy
for prevention of the condition.
Measures
undertaken by countries for improving patient access to new therapies, along
with modification in regulatory guidelines for facilitating faster drug review
and approval for HAE, are expected to contribute to market growth. For
instance, in July 2018, China’s National Health Commission (NHC) and State Drug
Administration (SDA) allowed pharmaceutical drug manufacturers to file for New
Drug Application (NDA) for therapies for rare diseases whose treatment is
currently not available in the country. The decision has allowed drug
manufacturers to use clinical trial data from outside China while filing for
NDA.
Request
a sample copy or view summary of this report@
https://www.grandviewresearch.com/industry-analysis/hereditary-angioedema-hae-therapeutics-market
Further key findings from the report suggest:
- The
C1-esterase inhibitor segment held the largest share in 2018 owing to high
usage rates of the products in on-demand and prophylactic treatment of HAE
- On-demand
treatment accounted for the dominant share in the market and is expected
to witness lucrative growth over the forecast period. Expected launch of
products in new geographies is likely to be a key growth driver for the
segment
- Based on
route of administration, intravenous drug therapies was one of the largest
segments. Subcutaneously-administered therapies, on the other hand, are
estimated to exhibit a lucrative CAGR of over 9.0% during the forecast
period owing to benefits such as convenient dosing and improved drug
effectiveness
- North
America dominated the overall hereditary angioedema therapeutics market in
terms of revenue in 2018. Growing number of cases of the condition,
favorable government programs, increasing awareness levels among patients,
and presence of highly expert healthcare professionals are factors
contributing to the major share of this regional market
- Asia Pacific
is expected to register lucrative growth over the forecast period owing to
improving healthcare infrastructure and high unmet medical needs.
Moreover, launch of new therapies for the treatment of the condition is
likely to facilitate market growth in the region
- Key players
include Ionis Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.;
Pharming Group N.V.; CSL Limited; Shire plc; Adverum Biotechnologies,
Inc.; Attune Pharmaceuticals, Inc.; and KalVista Pharmaceuticals, Inc.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment